<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 165 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page164.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=165">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 165 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 165</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=165"><img src="../thumb/165.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>134 / 2020-04                                             Cardio-Vascular Agents - 7.7.2 / 7.7.3 / 7.7.4 / 7.8
   consid. in sev.hypercholesterolaem.incl. heterozygous familial hy-  sity lipoprot cholester., with statin to reduc.elev.tot. cholester. & low-  Incr.if necess.to max.24 g/day. Incr.dos.gradual.with period.assess.of
   percholesterolaem.           density lipoprot.cholester.in homozyg.familial hypercholesterolaem.  lipid/ lipoprot.levels at interv.of not less than 4 wks.
   Homozygous familial hypercholesterolaem: Init.recomm.dos:   (S4) TABS, 37/7.5/0413  Prurit: 4-8 g dly.
   20 mg once dly.              704378-001: 10 mg, 30, R426,90  Bile acid malabsorpt.diarrh: Init. 4 g 3xdly. adjust.as need.
   Concom.ther.: Addit.effic.shown.with concom. fenofibrate in low.  Dosage: Lipid low.diet & weight loss program. where indic.to   Contraindications: Compl.bil.obstruct., phenylketonur., safety in
   triglycerid.& with niacin in incr. HDL-C lev., bile acid sequestrant.can   contin.dur.ther.  pregn.& lactat.not est., exudat./bldy.diarrh.
   be used. With concom.gemfibrozil.init.ther.with 5 mg once dly.& do   Recom.dos: 10 mg once dly.alone/with statin or fenofibrate.  Side effects: Constip., other GI disturbs., delay. absorpt.of comcom-
   not exceed 20 mg once dly    Contraindications: Pregn.& lactat., childr.und. 10 yrs., mod.to   itt.medic.& fat sol.vits., bleed. tendenc.due to hypoprothrombinaem.,
   Contraindications: Hypersens., act.liv.dis., concom. cyclospor., myo-  sev.hepat.impairm., safety & effic. with concom.fibrates other than   musculo-skelet.effs., CNS effs., tinnit., syncope, femor. nerve pain,
   pathy, safety & effic.in childr.not est., safety in pregn.& lactat.not est.  fenofibrate not stud.  paraesthes., uveit., ren.disturbs., weight loss/gain, incr.libido, swoll.
   Side effects: Common: Headache, dizzin., constipat., naus., abdom.  Side effects: Headache, fatig., GI disturbs., myalg., incr.ALT/AST &   glands, oed., dent.bleed./caries, GI rect./haemorrhoid.bleed., known
   pain, myalg., asthen. Uncomm: Prurit., rash, urticar. Rare: Myopathy   CPK, vir.infects., URTI, arthralg., back pain, cough., chest pain, diz-  duod.ulc.bleed., ulc.attack, pancreatit., rect. pain, diverticulit.eruc-
   incl. myosit., rhabdomyolys.occas.assoc.with ren.funct.impairm., skin/  zin., paraesthes., depress., thrombocytopen., hypersens. reacts.incl.  tat., hyperchloraem. acidos.in childr.(with prolong.use), osteoporos.,
   hypersens.reacts. incl. angioed., incr.hepat.transaminas., pancreatit.   angioed., pancreatit., hepatobil. disords., myopathy, rhabdomyolys.,   skin rash/ tong.& perin.area irritat., intestin.obstruct., calcif. mat.in
   V.rare: Jaund., hepatit.     erythema multiforme.          bil.tree, calcif.gall bladd., decr./incr. prothromb.times, ecchymos.,
   Warnings and special precautions: Consid. 40 mg only und.  Special precautions: Monit.INR when add.to warfar./other cou-  anaem., hypersens. reacts.
   specialist supervis.in sev. hypercholesterolaem. & high CV risk when   mar.anticoags., admin.bile acid sequestrant 2 hrs.bef.or 4 hrs.aft.,   Special precautions: Treatm.of dis.contribut.to incr.bld.cholestr.,
   treatm. goal not achiev.on 20 mg treatm./alt.ther., excess. alcoh.   with concom. statin, do LFT at init.of ther.& then accord.to statin.   contr.serum cholestr.& reduce weight bef.init.of therapy, red.dos.
   ingest., liv.dis.hist., ren.funct.monit.in pts. treat. with 40 mg dos.,   recomm., pts.to report S&S of myopathy & ther. and statin if applic   in constip., coron.artery dis., supplem.Vit.A, D & K if necess. NEVER
   incr.myosit.& myopathy incid. report.in pts.receiv.high.dos.& other   to be discont.if confirm., consid. gallblad. studies/alt.lipid low.ther.if   ingest dry form, always pre-mix. Take concomitt.medic.1 hr.bef.or
   HMG-CoA reduct. inhibit. tog.with cyclospor./fibric acid derivat. incl.  cholelithias. suspect., concom.cyclospor.  4-6 hrs aft. Questran. On discont.adjust dos.of digit.pts.pept.ulc.,
   gemfibrozil/nicotin.acid/azole antifung. & macrolide antibiot., monit.   Drug interactions: INR incr.with warfar., mean AUC decr.with   seek altern.therapy in diarrh.induc.by bile acid if no respon.with.3
   CPK lev.if S&S suggest.of myopathy pres.& discont.ther if myopathy   cholestyramine, fenofibrate/ gemfibrozil incr.conc., cyclospor.incr.  days, consid.folic acid treatm. where reduc.serum/red cell folate
   is diagn./susp., predispos.myopathy fact. eg. ren.impairm./advanc.  mean AUC for total ezetrol.  report., fluid & elctrol.deplet.in pts.with diarrh., discont.therapy if
   age/hypothyroid./ situat. where incr.plasma lev.poss., withdr.in ac.   adeq.reduct.not attain.
   ser. condit.suggest.of myopathy/pre-dispos.to ren. fail. developm.  Drug interactions: Delay/red.absorpt.eg. phenylbutaz., warfar.,
   second.to rhabdomyolys., incr. system.expos.in Asian pts., HIV-infect.
   pts.receiv. lopinavir/ ritonavir combin., cont.lact., women of childbear. 7.7.4  Others  chlorothiaz., propranolol, tetracycl., pen.G, phenobarb., aspir., thyroid
   potent.to use adeq. contracept., paed. exper.limit.to small numb.of   & thyroxine preps.& digit., pharmacokinet.of meds. undergo entero-
                                                              hepat.recirculat.poss.interfer. with.
   childr.8 yrs & old. with homozygous familial hypercholesterolaem.,   INEGY, MSD [P/S]
   sev.hepat./ren.impairm.      Ezetimibe 10(10; 10) mg, simvastatin 10(20; 40) mg
   Interactions: INR rais.with concom.warfar. theref.monit.recomm.,   Indications: Adjunct. ther.to diet to reduc.elev. tot.cholester.(tot.C)/
   steady state AUC  (0-t) incr. with concom.cyclosporin., C max & AUC ( O-t)   low density lipoprot.cholest.( LDL-C)/apolipoprot.B (Apo B) triglyc-  7.8   Plasma expanders
   incr.with gemfibrozil, steady state AUC  (0-24) incr.with concom. lopinavir   erid.(TG) & non-high-density lipoprot cholester.(non-HDL-C) and to
   & ritonavir combinat., oral antacids contain Mg & Al decr.plasma conc.  mod.incr.high density lipoprot.cholester. (HDL-C) in prim.(heterozy-  ALBUMIN HUMAN 20 % OCTAPHARMA, Octapharma
   See also MDR page 234.       gous familial & non-familial) hypercholesterolaem.or mix. hyper-  Human albumin 200 g/1000 ml
                                lipidaem., reduc.elev.tot.-C and LDL-C lev.in homozyg.familial hy-
   ZYSIM, Zydus [P/S]           percholesterolaem.            Indications: Restorat.& maint.of circulat.bld.vol. where vol.defic.
   Simvastatin.                 (S4) TABS, A39/7.5/0031; 0032; 0033   demonstrat. & use of a colloid appropr.
   Indications: Decr.elev.ser.tot.cholester.& LDL-cholester.in combin.  715237-001: 10/10 mg, 30, R304,19  (S4) IV INFUS. 36/30.3/0057
   with diet in prim. hypercholesterolaem. /heterozyg.familial hyper-  715238-001: 10/20 mg, 30, R304,19  713087-001: 20%, 50 ml, R396,08
   cholesterolaem. or mix hyperlipidaem.when respons. to diet & other   715240-001: 10/40 mg, 30, R304,19  713088-001: 20%, 100 ml, R792,15
   nonpharmacolog.meas. inadeq., reduc.coron.death/non-fat.MI/risk   Dosage: Cholest.low.diet bef.init.& dur.ther. Indiv. dos.accord.to   Dosage: Admin.IV.,warm preparat.to body/room temp.
   of undergo. myocard.revasculat.proced.& slow coron. artheroscle-  baseline LDL-C lev, recomm.ther. goal & respons. Admin.as sngl.  Conc., dos.& infus.-rate should be adjust.accord. to pt. indiv.requirem.
   ros.progress in pts.with est.coron.heart dis.& hypercholesterolaem.  dly.dos.in the even  Req.dos.depends on size of pt./ severity of trauma or illness/cont.
   unrespons.to diet.           Recomm.init.dos.10/20 mg/day. Dos.range: 10/10 mg through   fluid & prot. loss. Meas.adequacy of circulat.vol.& not plasma albu-
   (S4) TABS. 41/7.5/0666, 0667, 0668  10/80 mg/day. Analyse lipid lev.2 wks.aft.init.or titrat.of dos.& ad-  min lev.to determ.the dose reqd. Monit. haemodynam.perform.reg.
   710826-001: 10 mg, 30, R34,04  just dos.as reqd.           Contraindications: Do not mix with other meds./ whole bld. &
   710827-001: 20 mg, 30, R32,80  Homozyg.familial hypercholesterolaem: Recomm. dos.10/40   packed red cells., do not dil.with water for inj.
   710828-001: 40 mg, 30, R43,92  mg/day or 10/80 mg/day in the even. Adjunct. to other lipid low.  Side effects: Anaphylact.react./shock, confus. state, headache,
   Dosage: Admin.with food or on empty stomach  treatm./if such treatm.are unavail.  tachycard., bradycard., hypo-/hypertens., flush., dyspn., naus., urti-
   Hypercholesterolaem: Init.10 mg dly as sngl. dos.in even. Re-  Contraindications: Act.liv.dis., unexplain. persist. ser.transami-  car., angioneurot. oed., erythematos.rash, incr. sweat., fev., rigors.
   duc.if LDL-cholester.lev.&lt;1,94 mmol /L or tot.plasma cholester.  nas.elev., mod.to sev.hepat. impairm., pregn.& lactat., safety & ef-  Warnings and special precautions: Discont.& instit. appropr.
   lev.&lt;3,6 mmol/L              fic.in childr. not est.       treatm.if allerg./anaphylact.reacts. occur, observ.curr.medic.stand-
   Coron.heart dis: Init.20 mg dly as sngl.dos.in even.  Side effects: Headache, myalg., URTI, limb pain, GI disturbs., pan-  ards for treatm.in case of shock, condits.where hyper-volaem.& its
   Adjust dos.if reqd.at interv.of not less than 4 wks., to a max.of 80 mg   creatit., hypersens.syndr./reacts. incl. anaphylax./angioed.& erythe-  conseq./ haemodilut.could repres.a spec.risk for pt. incl.decompen-
   dly as sngl.even.dos.        ma multiforme, fatig., thrombocytopen., hepatit., jaund., hepat. fail.,   sat.card.insuffic./hypertens./ oesophag. varices/pulm.oed./haemorrh.
   Concom.ther: Bile acid sequestr: Admin.1 hr. bef./4 hrs.aft.  nerv.syst.disords., incr.liv.enzyme, incr.CPK, cholelithias., cholecystit.,   diathes./ sev. anaem./ren.& post-ren.anuria, sev.traumat. brain inj.,
   cholestyramine.              arthralg., myopathy, rhabdomyolys., depress., dizzin., paraesthes.,   adeq.hydrat.when concentrat.albumin is admin.& monit.careful.to
   Max.10 mg dly.dos. with concom.cyclospor. /fibrates /niacin.  anaem., periph. neuropathy, memory impairm., asthen., alopec., skin   guard against circulat. overload & hyper-hydrat., monit.electrol. &
   Contraindications: Ac./chron.liv.dis., unexplain. persist.ser.transam-  reacts., insomn., musc. cramps.  take appropr.steps to restore/maint.electrol. bal., control coagu-
   inas.elev., safety in pregn.& lactat./ porphyr.not est, female pts.of   Special precautions: Dos.not to exceed 10/10 mg dly.with con-  lat.& haematocrit if comparativ. large vol. o be replac.& take care
   child-bear. potent., safety & effic.in paed.pts.not est., concom. meds.  com.cyclospor./danazol or niacin great.or equal to 1 g/day but pref.  to ensure adeq.substitut. of other bld.constit.incl. coagulat. facts./
   inhibit.cytochrome P450 CYP3A4 not recomm.   to avoid. combin.use, dos.not to exceed 10/20 mg dly.with concom.  electrol./platelets & erythrocytes., hyper-volaem. poss.if dos.& rate
   Side effects: GI disturbs., pancreatit., anaem., neutropen., skin re-  amiodarone/verapamil and high.dos.to be avoid., avoid concom.  of infus.not adjust.to circulat. situat., discont.at first clinic.signs of
   acts., alopec., myalg., musc. cramps, myopathy, myosit., rhabdomy-  potent CYP3A4 inhibit. unless combin.ther.benefits outweigh risk, if   CV overload or incr.BP/rais. ven.press.& pulm.oed., controll.Na/ K
   olys., headache, dizzin., fatig., asthen., paraesthes., periph. neuropa-  itraconazole/ketoconazole/erythromycin/ clarithromycin or telithro-  diet, reduc. kidn.funct., infect.dis.due to transmiss.of infect. agents
   thy, hypersens.reacts incl.angioed., lupus-like syndrome, polymyalg.,   mycin unavoid.suspend Inegy ther.dur. course of treatm., advis.pts.  cannot be total.excl., use in pregn.& lactat. not est.although clinic.
   rheumat., vasculit., bld.dyscras., arthrit., arthralg., photosens., fev.,   of S&S & monit.for myopathy & discont.if myopathy occurs/suspect.,   exper.sugg.no harmful eff.expect.
   flush., malaise, dyspn., mass gain.  concom.fibrates not recomm., congenit. abnormalit.follow.HMG-CoA
   Special precautions: Cholester.low.diet bef.init. & dur.ther., feto-  intrauter. expos., dos.above 10/10 mg /day in sev.ren. insuffic., ad-  ALBUSOL 4%, 20%, NBI
   tox.& teratogen.in rats, incr. myopathy risk with concom.meds.caus.  min.2 hr.bef.or 4 hrs.aft.bile acid sequestrant, monit.liv.funct.when   Human plasma albumin deriv.from pool.human plasma, steril., pas-
   myopathy, substant. alcoh.consumpt., liv.dis.hist., predisposit. to   init.ther.& dur. ther. esp.if titrat.to 10/80 mg dos., monit.caref.if ser.   teur., test.& found non-react.to HBsAg & antibodies to HCV, HIV-1
   develop.ren.fail.second.to rhabdomyolys., monit. sev.ren.impairm.,   transamin.lev.elev.& if show progress.partic.to 3xULN persist.discont.  & HIV-2 virus.
   LFT advis.bef.start.treatm.& period. until 1 yr.aft.last dos.escalat.,   ther., substant.alcoh. consumpt., liv.dis.hist., monit.INR with concom.   Indications: Hypovolaem.shock assoc.with bld loss, trauma & surg.,
   discont.if transamin.lev.rise persist./incr.3x or more of ULN, determ.  warfar./ another coumar.anticoag/fluindione.  sev.burns (&gt;15% body surf. area) aft.24 hrs.if hypoproteinaem.devel-
   INR bef.init.ther.& monit.freq.esp.dur.dos. adjustm.with concom.cou-  Drug interactions: Potent CYP3A4 inhibit. reduc. simvastat.eliminat.  ops/to maint. plasma vol., in conjunct.with diuret.to promot. diures.
   mar.anticoags., pts.to report unexplain.musc.pain/tendern./weakn.,   incr.myopathy risk, myopathy risk incr.by fibrates & niacin at dos. great.   in hypoproteinaem.caus.by plasma prot.loss, maint.CV funct.follow.
   discont. if myopathy diagnos./suspect., risk vs. benef. of concom.  than/ equal to 1 g/day, myopathy risk incr.by cyclospor./ danazol/ami-  drain.large vol.of ascit.fluid. Albusol 20% only: As adjunct.in long-
   immunosuppress./fibrates/lipid low.niacin dos., withdr.tempor.in pts   odarone/verapamil/diltiazem & fusidic acid, mean ezetimibe AUC   term dialys.pts.suscept.to shock & hypotens./ dialys.pts.who are
   receiv. cyclospor. if system.azole derivat.antifung.reqd.  decr.with cholestyramine, fenofibrates & gemfibrozil incr. ezetimibe   hypovolaem.& intoler.of large vol.of crystalloid infus.
   Drug interactions: Poss incr.plasma lev.eg. concom. cyclospor./itra-  conc., simvastat.mod.potent. coumar. anticoags.effs, mean ezetimibe   (S4) IV INFUS. T/30.3/738, 739.
   conazole/ketoconazole/ erythromyc./ clarithromyc./HIV prot.inhibit.&   AUC incr.with cyclospor.  802840-019: 4%, 8 g/200 ml, 200 ml, R458,50
   nefazodone, digoxin lev.incr., anticoag.eff.of coumar. anticoags.incr.,   QUESTRAN LITE, Equity [P/S]  802867-006: 20%, 10 g/50 ml, 50 ml, R384,45
   bile acid sequestr.decr. bioavailabil.  Anhydr.Cholestyramine. (16,8 mg Phenylalanine from aspartame   802859-003: 20%, 20 g/100 ml, 100 ml, R768,90
                                as sweetner).                 Dosage: Admin.IV. at rate of about 1 ml/min. Infus. rate & tot.vol.to
                                Indications: Serum, low density cholester.& lipoprot. lev.reduct.in   be infused depend.on indicat. & haemodynam.respons. Whole bld./
   7.7.3   Cholesterol absorption   prim.hypercholesterolaem.in conjunct.with appropr.diet or as adjunct.  pack. cells transfus.may be neccess.aft.admin.of large vol.of albumin
                                                              20 %. Dos.guidelines:
                                to diet when respon.is not adeq., low.elevat.cholester.in combin.hy-
          inhibitors            percholesterolaem.& hypertriglyceridaem., prurit.in part.bil.obstruct.,   Hypovolaem. & ascites: Adults: Init.dos: Approx. 25 g as IV infus.
                                                              If clinic.respons.not achiev. within 15-30 mins., addit.dos.may be giv.
                                diarrh. assoc.with bile acid malabsorpt.
                                (S2) POWD. D/7.5/39.          Paed.dos: Init.approx.2,5-12,5 g in tot.or 0,5-1 g/kg bm as IV infus.
   EZETROL 10 MG, MSD [P/S]     836559-002: 4 g/sachet, 50 sachets, R423,69  If adeq.respons.not achiev. within 15-30 mins., addit.dos.may be giv.
   Ezetimibe                    Dosage: Mix with fluid.       Burns: Adults & paed.dos: Recomm.therapy start with admin. of
   Indications: In prim.hypercholesterolaem.as adjunct. ther.to diet ad-  Cholesterol reduct: Adults 4 g. Recommend. dos.sched.is 2 dly.but   large vol.of crystalloid infus.to maint.plasma vol. Albumin may be
   min.with reduct.inhibit.or alone to reduc.elev.tot.cholester.& low-den-  may be admin.in 1-4 dos./ day, may be incr.to 8 g in the morn.& even.   add.aft.24 hrs. at init.dos.of 25 g, adjust dos.theraft.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page164.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page160.html">160</a>&nbsp;&nbsp;&nbsp;<a href="page161.html">161</a>&nbsp;&nbsp;&nbsp;<a href="page162.html">162</a>&nbsp;&nbsp;&nbsp;<a href="page163.html">163</a>&nbsp;&nbsp;&nbsp;<a href="page164.html">164</a>&nbsp;&nbsp;&nbsp;<a href="page165.html">165</a>&nbsp;&nbsp;&nbsp;<a href="page166.html">166</a>&nbsp;&nbsp;&nbsp;<a href="page167.html">167</a>&nbsp;&nbsp;&nbsp;<a href="page168.html">168</a>&nbsp;&nbsp;&nbsp;<a href="page169.html">169</a>&nbsp;&nbsp;&nbsp;<a href="page170.html">170</a>
             </td>
             <td width="35%"><a href="page166.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page166.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
